Articles tagged "Kidney transplantation"

2020 American Transplant Congress
Kidney Transplant Recipients with De Novo Donor Specific Antibody is Associated with Increased Risk of Developing BK Viremia
S. Kareem¹, L. Suresh², A. Gundroo¹, J. Von Viger¹, S. Chang¹
¹Internal Medicine, University of Buffalo, Buffalo, NY, ²Pathology, University of Buffalo, Buffalo, NY
*Purpose: Background: De novo donor specific anti-HLA antibodies (dnDSA) has profound effect on the renal graft long-term function and survival. Studies has shown identifications of…
2020 American Transplant Congress
HLA Mismatch Immunogenicity: Are We Predicating Mismatches That Induce De Novo DSA Development or That Do Not?
V. Jucaud¹, L. Rebellato², K. Briley², C. Haisch², S. Kendrick³, H. Jones³, K. Mclawhorn³, D. Leeser², M. Everly¹
¹Terasaki Research Institute, Los Angeles, CA, ²East Carolina University, Greenville, NC, ³Eastern Nephrology Associates, Greenville, NC
*Purpose: Although the development of de novo donor-specific anti-HLA antibodies (dnDSA) remains a major risk factor for poor long-term kidney allograft outcomes, the prediction of…
2020 American Transplant Congress
Single Center Experience in Using Donor-Derived Cell-Free DNA in Kidney Transplant
P. Homkrailas¹, S. Lee², B. Kandagedon¹, G. Danovitch¹, S. Bunnapradist¹
¹Medicine, Division of Nephrology, Kidney and Pancreas Transplant Programs, UCLA, Los Angeles, CA, ²Department of Pharmacy, UCLA, Los Angeles, CA
*Purpose: While the gold standard for diagnosing allograft rejection in kidney transplant recipients (KTX) continues to be histopathologic evaluation, it has been well recognized that…
2020 American Transplant Congress
Mitochondrial Metabolism is Enriched Following Normothermic Ex-Vivo Kidney Perfusion of Grafts Procured Following Cardiac Death
P. Urbanellis¹, C. McEvoy¹, L. Mazilescu¹, S. Ganesh¹, R. John¹, I. Mucsi¹, A. Ghanekar¹, D. Bagli², A. Konvalinka¹, L. Robinson², M. Selzner¹
¹University Health Network, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada
*Purpose: Normothermic ex-vivo kidney perfusion (NEVKP) preservation has demonstrated superior graft outcomes for kidneys procured following donation-after-cardiac death (DCD) over static cold storage (SCS). To…
2020 American Transplant Congress
Rabbit Anti-Thymocyte Globulin versus Anti-T Lymphocyte Globulin Rescue Therapies in Delayed Graft Function after Kidney Transplantation from Donors after Cardiac Death
H. Yang¹, Y. Shi², X. Li¹, C. Long¹, H. Li³, Z. Wang³
¹Department of Organ Transplantation, Jiangxi Provincial People’s Hospital Affiliated to Nanchang University, Nanchang, China, ²Department of Pathology, Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ³Department of Urologic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
*Purpose: Delayed graft function (DGF) is common in recipients of kidney transplants from donation after cardiac death (DCD) donors, induction therapy with monoclonal or polyclonal…
2020 American Transplant Congress
Dual Kidney Transplantation Offers a Safe and Effective Way to Use Kidneys from Deceased Donors Older Than 70 Years
K. Lee, J. Park, S. Cha, M. Kim
Samsung Medical Center, Seoul, Korea, Republic of
*Purpose: Dual kidney transplantation (DKT) offers a way to extend the use of kidneys from expanded criteria donors (ECDs). Here, we compared the outcomes of…
2020 American Transplant Congress
Post-Transplant Collagen I and Collagen III Antibodies and Antibody-Mediated Rejection in Kidney Transplantation Recipients
S. Park¹, S. Yang², J. Kim², Y. Kim², Y. Kim², J. Ha², K. Moon², E. Song², H. Lee²
¹Armed Forces Capital Hospital, Gyeonggi-do, Korea, Republic of, ²Seoul National University Hospital, Seoul, Korea, Republic of
*Purpose: An emerging role of non-human leukocyte antigen (HLA) antibodies on the risk of antibody-mediated rejection (AMR) has been suggested, although most of their non-HLA…
2020 American Transplant Congress
Multi- National Survey among Nephrologists and Transplant Surgeons about the Suitability and Acceptance of the Marginal Live Kidney Donors with Family History of Kidney Disease
Z. Arabi¹, S. Kaysi², A. Altheaby¹, E. Elhassan¹, M. Bukhari³, A. Mateen¹, A. Hamad⁴
¹KAMC, Riyadh, Saudi Arabia, ²CHR Orleans, Orleans, France, ³Taif University, Taif, Saudi Arabia, ⁴The Regional Medical Center, Orangeburg, SC
*Purpose: Kidney transplantation from a living donor is the best treatment option for End Stage Kidney Disease. Considering the shortage of available organs, transplant centers…
2020 American Transplant Congress
Clinical Implications of Tacrolimus Time in Therapeutic Range in Urban Renal Transplant Recipients Under an Early Corticosteroid Withdrawal Protocol
D. Pierce, P. West-Thielke, Z. Hajjiri, S. Gaitonde, I. Tzvetanov, E. Benedetti, A. Lichvar
University of Illinois at Chicago, Chicago, IL
*Purpose: Tacrolimus displays wide inter- and intra-patient variability, necessitating therapeutic drug monitoring. Assessing the duration of time in therapeutic range (TTR) is an additional tool…
2020 American Transplant Congress
Evaluation of Cytomegalovirus Prophylaxis in Low and Intermediate Risk Kidney Transplant Recipients Receiving Lymphocyte-Depleting Induction
H. Stamps, K. Linder, D. O'Sullivan, F. Cheema, H. Kutzler
Hartford Hospital, Hartford, CT
*Purpose: This study evaluates if choice and duration of Cytomegalovirus (CMV) prophylaxis based on donor (D) and recipient (R) CMV serostatus impacts the incidence of…